- Reuters•3 months ago
India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said. The world's fifth-largest maker of generic drugs was the first among its Indian peers to enter the roughly $5 billion U.S. dermatology space by acquiring a controlling stake in Israel's Taro Pharmaceutical Industries Ltd in 2010.
- Bloomberg•4 months ago
Indian drugmakers are embarking on a research spending spree to master more complex therapies and their billionaire founders look willing to absorb the costs.
- Bloomberg•6 months ago
Shares of Lupin Ltd., India’s second-biggest drugmaker by market value, pared some of their losses after saying observations made by the U.S. Food and Drug Administration on one of its key factories were ...
Lupin Limited (LUPIN.NS)
NSE - NSE Delayed Price. Currency in INR
|Day's Range||1,455.00 - 1,531.80|
|52wk Range||1,280.00 - 2,129.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||25.74|
|Avg Vol (3m)||1,077,850|
|Dividend & Yield||N/A (N/A)|